Trial
NCT03630809
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
—
Condition
Breast Cancer
Intervention
HER2 DC1 Vaccine
Why stopped
Quality of the data originating from prior versions of the protocol has been affected by protocol deviations triggered by the COVID-19 pandemics
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-25